Bought the ticket, hasn't taken the ride: the company has already paid for its next stage and is now waiting to be paid
The model's full reasoning — Q3 2022 call → NOThe question asks whether management describes a situation where the company has already spent or committed resources for a stage of business it has not yet been paid back for — i.e., the spending is done, the return is still outstanding, and management treats the payback as a matter of time. Let me examine the transcript for evidence of this pattern. Key elements to look for: 1. Spending already done (cash, resources, people, capability installed) 2. Return still largely outstanding (results not yet showing the benefit) 3. Management treats payback as a matter of time (work in motion, business in view) Looking at the transcript: - The company is developing CUE-101 and CUE-102, clinical-stage biopharma. - They have clinical trials ongoing. The trials are already running — patients are being treated. - The company has spent on R&D, manufacturing, etc. - The data from trials is emerging — they report on monotherapy and combination data. - They talk about "derisking" the platform — CUE-101 has derisked the entire platform, allowing CUE-102 to start at a higher dose without additional toxicology studies. Is there a specific situation where management describes: - Money already spent on something - The return not yet arrived - And the payback is a matter of time? Let me look for specific examples: 1. CUE-102: They've started the trial, treated first patient. The trial is ongoing. They expect data by mid-2023. The spending on CUE-102 development is done (they got IND approval, started trial), but the return (clinical data, potential market) is still outstanding. However, is this "large relative to the company"? The company is spending on R&D generally. 2. The combination trial: They've enrolled 10 patients, expect to report on full 20 in Q2 next year. The spending on the trial is ongoing, but the return (registration path) is not yet. 3. The monotherapy trial: They have survival data emerging, expect mature data by end of year. Let me think about whether management describes a specific outlay already made with a return still outstanding. Actually, looking more carefully — the company is a clinical-stage biotech. Its entire business model is spending on R&D to develop drugs. The "spending" is ongoing R&D. The "return" would be future drug approvals and sales.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| SLDP | Solid Power, Inc. | Q1 2023 | 2023-05-08 | C+ |
| KE | Kimball Electronics, Inc. | Q3 2023 | 2023-05-06 | C+ |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| STC | Stewart Information Services Corporation | Q1 2022 | 2022-04-29 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| HNRG | Hallador Energy Company | Q3 2021 | 2021-11-09 | C+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| RCL | Royal Caribbean Cruises Ltd. | Q1 2016 | 2016-04-29 | C+ |
PRIM · Q2 2018 → YESThe question is about whether management describes having already spent money or resources for a larger operation, but the revenue from that hasn't arrived yet. YES The transcript shows management describing the Willbros acquisition as a completed outlay: closed June 1, $165 million total paid ($38.4 million cash for shares + $123.2 million debt settlement + $3.1 million fees), net cash $111 million, funded by revolver, then refinanced 220 million term loan. This is treated as already done, not planned. The return is still largely outstanding: only one month of Willbros operations reported ($61 million revenue, $6.8 million gross profit, $2.9 million operating income in June), merger-related expenses $7.
PSX · Q4 2016 → YESThe question is about whether management describes having already spent money or resources for a larger operation, but the returns haven't come yet, and they expect them soon as a matter of time. YES Management describes the U.S. Gulf Coast Petrochemicals Project as already substantially paid for: capital spending is “reduced following the completion of the project” and “down significantly” compared with last year, with roughly $1 billion of CapEx no longer available for distribution.
TGI · Q2 2017 → YESThe question is about whether management describes having already spent money or resources for a larger operation that hasn't paid back yet. YES The transcript shows management describing a clear situation matching all three criteria. On slide 13, they report "$126 million" of year-to-date investments in development programs as a completed cash outflow ("used $126 million"), with incremental customer financing providing $100 million offset.